Karolinska Development's portfolio company Modus Therapeutics sees potential for its drug candidate sevuparin in the treatment of anemia
12 5월 2023 - 3:45PM
Karolinska Development's portfolio company Modus Therapeutics sees
potential for its drug candidate sevuparin in the treatment of
anemia
STOCKHOLM, SWEDEN May 12, 2023. Karolinska Development AB
(Nasdaq Stockholm: KDEV) today announces that its portfolio company
Modus Therapeutics, in collaboration with a world-leading research
group, has generated data showing that its drug candidate sevuparin
has the potential to be developed as a treatment for anemia in
patients with certain chronic diseases. The results will be
presented at the European Hematology Association's annual meeting
on June 8-11.
Modus Therapeutics has a well-established collaboration with
Professor Maura Poli and her research team at the University of
Brescia, Italy. The research group has now generated data showing
that the company's drug candidate sevuparin is able to strongly
suppress hepcidin at dose levels that are not considered to risk
causing side effects. High levels of hepcidin are considered to be
involved in the onset and progression of the type of anemia that
often complicates chronic kidney disease and chronic inflammatory
diseases. Hepcidin is also thought to play a role in the
development of resistance to current standard treatments for
anemia. The research findings support the possibility of developing
sevuparin as a new treatment for hepcidin-related disorders such as
anemia in patients with chronic kidney disease and other chronic
inflammatory diseases. Sevuparin is already being developed as a
potential treatment for sepsis/septic shock. “The results
generated within Modus Therapeutics' collaboration with Professor
Poli's world-leading research team provide a solid platform for
developing sevuparin as a potential treatment for anemia. This
broadening of therapeutic indications for the drug candidate
strengthens our portfolio company's ability to generate significant
value for large groups of patients and for its shareholders," says
Viktor Drvota, CEO, Karolinska Development.
Karolinska Development's direct ownership interest, and indirect
ownership interest via KDev Investment, in Modus Therapeutics
amounts to 38% and 17%, respectively.
The abstract, which will be presented at the European Hematology
Association's annual meeting in Frankfurt am Main, Germany is
titled “The non-anticoagulant heparinoid compound, sevuparin,
strongly reduces hepcidin expression in cells, in mice and in
healthy volunteers”. The presentation includes preclinical,
clinical, and mechanistic data describing the potential of
sevuparin to inhibit hepcidin, which is considered the master
regulator of iron within the body. The abstract can be found here:
https://library.ehaweb.org/eha/2023/eha2023-congress/387983
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982
52 02, e-mail: viktor.drvota@karolinskadevelopment.com
Johan Dighed, General Counsel and Deputy CEO, Karolinska
Development ABPhone: +46 70 207 48 26, e-mail:
johan.dighed@karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development ABKarolinska
Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences
investment company. The company focuses on identifying breakthrough
medical innovations in the Nordic region that are developed by
entrepreneurs and leadership teams. The Company invests in the
creation and growth of companies that advance these assets into
commercial products that are designed to make a difference to
patients' lives while providing an attractive return on investment
to shareholders.
Karolinska Development has access to world-class medical
innovations at the Karolinska Institutet and other leading
universities and research institutes in the Nordic region. The
Company aims to build companies around scientists who are leaders
in their fields, supported by experienced management teams and
advisers, and co-funded by specialist international investors, to
provide the greatest chance of success.
Karolinska Development has a portfolio of eleven companies
targeting opportunities in innovative treatment for
life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment
professionals with a proven track record as company builders and
with access to a strong global network.
For more information, please visit
www.karolinskadevelopment.com.
Karolinska Development Ab (LSE:0P3C)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Karolinska Development Ab (LSE:0P3C)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024